_(2).png)
Gov’t focusing on AstraZeneca's COVID-19 vaccine for VI – Hon Malone
The Health Minister made the announcement on December 17, 2020, during a COVID-19 update to the territory where he assured that the Ministry of Health and its stakeholders will immediately begin the mammoth task of planning for the introduction of the vaccine in the Territory.
“Given the lack of access to the BVI by direct flights and consequent transit times together with the specific cold chain requirements, efforts will focus on the AstraZeneca vaccine which is compatible with our current cold chain and logistics for management of vaccines through the Territory’s expanded programme of immunization,” Hon Malone said.
“This will include the involvement of multiple stakeholders from the public, private, and non-government sectors coupled with a significant health promotion effort.”
Gov’t aware of myths surrounding vaccination – Hon Malone
He said, however, that authorities are also well aware that there are many misconceptions, myths and untruths surrounding COVID-19 vaccination, all of which will need to be addressed in the coming months.
Further, Hon Malone said that the Health Ministry has signed on to the WHO GAVI Covax initiative which gives eligible countries access to COVID-19 vaccines, in addition to UK commitment to provide the territory with access to more COVID-19 vaccines.
“The public can rest assured that the vaccine will be offered on a voluntary basis with best efforts to provide adequate information for persons seeking vaccination. As we advance our plans more information will be forthcoming to the public with regards to COVID-19 vaccination,” Hon Malone said.
.png)
.png)
.png)
_(1)_01.png)
.png)
Follow Us On
31 Responses to “Gov’t focusing on AstraZeneca's COVID-19 vaccine for VI – Hon Malone”
"Sixty-nine participants in the UK weekly 6,638-person COVID-19 testing group were infected with asymptomatic COVID-19, including 29 of 3,288 (0.9%) in the vaccine group and 40 of 3,350 (1.2%) in the control group, translating to a 27% vaccine effectiveness against asymptomatic spread.
Of the group receiving an initial half-dose of COVID-19 vaccine, 7 of 1,120 (0.6%) participants in the vaccine group and 17 of 1,127 participants (1.5%) in the control group had asymptomatic infections, equating to a vaccine effectiveness against asymptomatic spread of 59%. In those who received two standard doses, 22 of 2,168 participants (1%) in the vaccine group and 23 of 2,223 in the control group (1%) had asymptomatic infection, indicating a 4% vaccine effectiveness against asymptomatic spread."
"AstraZeneca attributed the surprise deviation in trial dosing (ie, the half-dose/standard dose regimen) in the 1,367-participant subset to a manufacturing error in the quantification methods used between batches, resulting in some vials having 50% less vaccine than the others.
Why this regimen would be much more effective than the intended dose has not been explained, although the researchers have theorized that the lower first dose more closely mimicked that of an infection, while other experts saying that it could have been the result of the different size and type of participants in the subgroup.
The subset receiving the lower first dose didn't include participants older than 55 years—who tend to mount a weaker immune response than their younger counterparts—because the different dosage was given early in the trial, before older adults were recruited."
No myths because clearly vaccines made in months.
We are bot going to be a part of this trial and error let’s face it a year or more from now many will get sick die from this vaccine or any COVID related vaccines.
I guess who die die who live live who get crippled that’s them businesses life goes on the world goes on.
Trini setting up a place for vaccinated ppl to be resuscitated after being inoculated they claim Allergic reactions .
As an economist let me inform you about Astra Zeneca the cost is so low as they are not making any profit from any of the vaccine, the charge only covers their costs nothing more.